Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

Hiroki Ishihara; Koichi Nishimura; Yuki Nemoto; Shinsuke Mizoguchi; Takayuki Nakayama; Hironori Fukuda; Hiroaki Shimmura; Yasunobu Hashimoto; Kazuhiko Yoshida; Junpei Iizuka; Tsunenori Kondo; T. Takagi

doi:10.1093/jjco/hyag037

February 17, 2026Japanese Journal of Clinical Oncology

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to evaluate the effectiveness and safety of third-line therapy after prior treatments in advanced renal cell carcinoma.
Analyzed real-world patient outcomes following third-line treatment.
Investigated the sequence of immune checkpoint inhibitors and VEGFR-TKIs.
Assessed toxicity and clinical effectiveness of the treatments.
Third-line therapy demonstrated feasibility with effective clinical outcomes.
Toxicity levels were manageable among treated patients.
Overall treatment strategy showed promise for advanced RCC management.

Implication

Observational study finds effective third-line therapy in advanced RCC, suggesting good management of outcomes.

Abstract

Third-line systemic therapy following ICI combinations and sequential VEGFR-TKIs shows feasible clinical effectiveness and manageable toxicity in real-world patients with advanced RCC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ishihara et al. (2026) studied this question.

synapsesocial.com/papers/69a7cce8d48f933b5eed8cb5 https://doi.org/10.1093/jjco/hyag037

View at Publisher

Ask AI

Bookmark

Share

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Real-world outcomes of third-line systemic therapy after immune checkpoint inhibitor combinations and subsequent VEGFR-TKIs in advanced renal cell carcinoma

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading